PIAS2

Across TCGA pan-cancer cohorts, PIAS2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PIAS2 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PIAS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PIAS2 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

SCLC, STAD, and UCEC are the cancer types where PIAS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
STAD	DFS	Median	II,III,IV	1.000	0.628	.016	12	view →
UCEC	DFS	Median	All	0.962	0.618	.011	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PIAS2–SCLC (OS)

Open the SCLC breakdown →